Dr. Cantuaria is the Chief Science Officer of Metanoi. He is a distinguished physician-scientist and entrepreneur with over two decades of leadership in oncology research and clinical care. Board-certified in both Gynecologic Oncology and Obstetrics and Gynecology in the U.S. and Brazil, Dr. Cantuaria has served as Chairman and Medical Director of the Northside Hospital Cancer Program in Atlanta, Georgia since 2011. He has held principal investigator roles in major National Cancer Institute (NCI) research programs and has been honored repeatedly as a "Top Doctor" by Castle Connolly and local peer surveys. Dr. Cantuaria is a published author of over 40 peer-reviewed articles and is a recognized authority in cancer biology, clinical trials, and translational medicine. He holds an MD from the University of Brasilia and completed his residency and fellowship at the University of Miami.

Stephan Jackman is a dynamic biotechnology executive with broad leadership experience spanning clinicaln development, operations, and strategic planning. Mr. Jackman also serves as CEO of Alzamend Neuro, where he successfully led the company through an IPO onvNasdaq and raised over $60 million in capital. He previously held leadership roles at Exit 9 Technologies and Ennaid Therapeutics, managing capital raises, clinical trial operations, and strategic growth initiatives. Mr. Jackman hasmanaged budgets totaling over $100 million and CAPEX/OPEX projects exceeding $500 million.  He has also held positions of increasing responsibility at Novartis Pharmaceuticals Corporation, L’Oréal USA, SBM Management Services and Family Intervention Services. He holds a Master of Science in Management and a Bachelor of Engineering in Mechanical Engineering from Stevens Institute of Technology.